Tips for Submitting a
Strong Concept

The Biopharma Development Access Program is designed to support biotechnology and pharmaceutical teams seeking proteomic insight to inform development-stage programs.

Submissions are evaluated based on the clarity of the biological question, the feasibility of the proposed study, and the potential for proteomic data to generate meaningful insights for therapeutic development.

The concept brief submission is intentionally concise. The guidance below highlights what reviewers look for when evaluating submissions.

Clearly Define the Development Question

Strong submissions start with a specific biological or development-stage question

Examples include:

• Understanding the mechanism of action of a therapeutic candidate
• Investigating biological pathways associated with treatment resistance
• Identifying protein biomarkers associated with response or clinical outcome
• Evaluating target engagement or pathway modulation in preclinical models

Clearly articulating the question helps reviewers determine whether proteomic analysis is well suited to generate meaningful insight.

Focus on a Decision-Relevant Study

The most compelling submissions describe studies where proteomic data could inform a development decision. Projects that connect proteomic data to actionable biological insight are particularly well suited for the program.

Describe the Study Design at a High Level

The concept brief should include a concise description of the proposed study design.

Helpful details may include:

• Sample type (e.g., plasma, serum, CSF)
• Study cohorts or comparison groups
• Number of samples available
• Experimental context (clinical samples, preclinical models, or translational cohorts)

Submissions do not require a full experimental plan, but providing enough context helps reviewers assess feasibility.

Highlight Where Unbiased Proteomics Can Add Unique Insight

Deep, unbiased proteomics can provide insight beyond what is available through genomics, transcriptomics, or targeted proteomics approaches.

Strong submissions briefly describe why unbiased protein-level measurements are important for the biological question being addressed.

Keep the Submission Concise

The Biopharma Development Access Program concept brief is designed to be quick to complete.

A clear description of the development question, study context, and expected insight is typically sufficient for evaluation.

Applicants may provide additional information or supporting materials if helpful, but this is not required.

Final Tip

Submissions that clearly describe how proteomic data could advance understanding of a development-stage program are the most compelling. Even a concise concept brief can effectively convey the biological rationale and potential impact of the proposed study.